Peptide GAM immunoadsorption therapy in primary membranous nephropathy (PRISM): Phase II trial investigating the safety and feasibility of peptide GAM immunoadsorption in anti‐PLA2R positive primary membranous nephropathy
Journal of Clinical Apheresis2017Vol. 33(3), pp. 283–290
Citations Over Time
Patrick Hamilton, Durga Kanigicherla, Prasanna Hanumapura, Lars Walz, Dieter Krämer, Moritz Fischer, Paul Brenchley, Sandip Mitra
Abstract
With proven efficacy in removing IgG antibodies and its use as a relatively safe treatment option in a multitude of conditions, immunoadsorption has the potential to offer patients with primary MN a more directed therapy free from the short and long-term side-effects generally seen in this condition.
Related Papers
- → The Six Year Experience of Plasmapheresis in Patients with Myasthenia Gravis(2000)43 cited
- → Plasmapheresis for the Treatment of Antibody-Mediated Rejection in Lung Transplant Recipients(2017)2 cited
- [Therapeutic apheresis in multiple sclerosis].(2003)
- [Plasmapheresis in acute phase of multiple sclerosis and neuromyelitis optica].(2014)
- [Double filtration and immunoadsorption plasmapheresis in Guillain-Barré syndrome].(1996)